Cytek Biosciences, Inc.CTKBEarnings & Financial Report
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Revenue
$41.5M
Gross Profit
$20.2M
Operating Profit
$-15.0M
Net Profit
$-11.4M
Gross Margin
48.6%
Operating Margin
-36.1%
Net Margin
-27.5%
YoY Growth
-7.6%
Cytek Biosciences, Inc. Q1 FY2025 Financial Summary
Cytek Biosciences, Inc. reported revenue of $41.5M (down 7.6% YoY) for Q1 FY2025, with a net profit of $-11.4M (down 84.8% YoY) (-27.5% margin). Cost of goods sold was $21.3M, operating expenses totaled $35.1M.
Key Financial Metrics
| Total Revenue | $41.5M |
|---|---|
| Net Profit | $-11.4M |
| Gross Margin | 48.6% |
| Operating Margin | -36.1% |
| Report Period | Q1 FY2025 |
Revenue Breakdown
Cytek Biosciences, Inc. Q1 FY2025 revenue of $41.5M breaks down across 2 segments, led by Sales Channel Directly To Consumer at $30.0M (72.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Sales Channel Directly To Consumer | $30.0M | 72.3% |
| Sales Channel Through Intermediary | $11.5M | 27.7% |
Cytek Biosciences, Inc. Revenue by Segment — Quarterly Trend
Cytek Biosciences, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Sales Channel Directly To Consumer and Sales Channel Through Intermediary) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Sales Channel Directly To Consumer | — | $37.7M | $33.5M | $30.0M |
| Sales Channel Through Intermediary | — | $14.6M | $12.1M | $11.5M |
Cytek Biosciences, Inc. Annual Revenue by Year
Cytek Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $201.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $201.5M |
| 2024 | $200.5M |
| 2023 | $193.0M |
| 2022 | $164.0M |
Cytek Biosciences, Inc. Quarterly Revenue & Net Profit History
Cytek Biosciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $62.1M | +8.1% | $-44.1M | -70.9% |
| Q3 FY2025 | $52.3M | +1.5% | $-5.5M | -10.5% |
| Q2 FY2025 | $45.6M | -2.2% | $-5.6M | -12.2% |
| Q1 FY2025 | $41.5M | -7.6% | $-11.4M | -27.5% |
| Q4 FY2024 | $57.5M | -1.3% | $9.6M | 16.8% |
| Q3 FY2024 | $51.5M | +7.3% | $941.0K | 1.8% |
| Q2 FY2024 | $46.6M | -6.2% | $-10.4M | -22.4% |
| Q1 FY2024 | $44.9M | +21.0% | $-6.2M | -13.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.9M | $46.6M | $51.5M | $57.5M | $41.5M | $45.6M | $52.3M | $62.1M |
| YoY Growth | 21.0% | -6.2% | 7.3% | -1.3% | -7.6% | -2.2% | 1.5% | 8.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $492.1M | $483.7M | $491.2M | $499.5M | $482.6M | $493.3M | $494.9M | $461.5M |
| Liabilities | $99.5M | $94.6M | $105.8M | $103.8M | $103.0M | $115.8M | $116.3M | $119.8M |
| Equity | $392.6M | $389.1M | $385.5M | $395.7M | $379.6M | $377.6M | $378.6M | $341.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $4.0M | $6.2M | $13.2M | $2.0M | $-125000 | $108000 | $-3.9M | $-771000 |